title: Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.
abstract: The aim of this study was to investigate the rate of progression in Parkinson's disease (PD) with 6-[(18)F]fluoro-L-dopa (FDOPA) positron emission tomography (PET). We investigated 21 patients with PD and eight healthy controls. Ten of the patients were de novo at the time of the first PET scan and antiparkinsonian medication was started thereafter, with a favourable response. A FDOPA PET scan was carried out twice at an approximately 5-year interval. The regions of interest were drawn on individual magnetic resonance imaging (MRI) images, matched with the PET images. At the first PET scan, in PD patients the mean k(i)(occ) (x 10(-3) min(-1)) in the anterior putamen was 5.6 +/- 2.7 (mean +/- S.D.; 55% of the control mean) and in the posterior putamen 4.5 +/- 2.4 (45% of the control mean). The k(i)(occ) value for the caudate nucleus was 7.5 +/- 2.1 (x 10(-3) min(-1); 76% of the control mean). The FDOPA uptake declined by the time of the second PET scan and the annual rate of decline was 8.3 +/- 6.3% (P < 0.001) of the baseline mean in the anterior putamen and 10.3 +/- 4.8% (P < 0.001) in the posterior putamen. In the caudate nucleus, FDOPA uptake decreased by 5.9 +/- 5.1% (P < 0.001) of the baseline mean per year. The estimated preclinical period was longest for the posterior putamen being 6.5 years. For the anterior putamen the preclinical period was 4.6 years. In the caudate nucleus, the estimated FDOPA uptake was at normal level at disease onset. In healthy controls, there was no significant decline in FDOPA uptake in any striatal subregion. Our results suggest that the disease process in PD first affects posterior putamen, followed by the anterior putamen and the caudate nucleus, but once started, the absolute rate of decline is the same. In healthy controls, no significant decline in FDOPA was detected.
authors.affiliation: Department of Neurology, and Turku PET Centre, University of Turku, Turku, Finland.
authors.forename: E
authors.initials: E
authors.lastname: Nurmi
authors.forename: H M
authors.initials: HM
authors.lastname: Ruottinen
authors.forename: J
authors.initials: J
authors.lastname: Bergman
authors.forename: M
authors.initials: M
authors.lastname: Haaparanta
authors.forename: O
authors.initials: O
authors.lastname: Solin
authors.forename: P
authors.initials: P
authors.lastname: Sonninen
authors.forename: J O
authors.initials: JO
authors.lastname: Rinne
mesh_terms: D000328:Adult; D000368:Aged; D002421:Caudate Nucleus / Q000000981:diagnostic imaging; D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000000981:diagnostic imaging*; D011699:Putamen / Q000000981:diagnostic imaging; D014055:Tomography, Emission-Computed
chemical_list: C043437:fluorodopa F 18; D004295:Dihydroxyphenylalanine